Combination Inhalers for Upper Airway Diseases
|発行||Greystone Research Associates||商品コード||337817|
使いやすさ、および多くの患者にとって上気道疾患に関連した症状の管理が改善したことから、 コンビネーション吸入薬の開発活動および製品普及は大幅に増加しています。コンビネーション吸入薬は主に吸入コルチコステロイドと気管支拡張剤の組み合わせで構成されています。これらの製品は、2020年代後半に大幅に増加すると予測される2つの市場 - 喘息およびCOPD (慢性閉塞肺疾患) の市場で大きな商業的成功を収めています。
当レポートでは、コンビネーション (併用) 経口吸入薬の市場について調査し、複数の薬剤を送達する経口吸入器技術、製品の技術課題と発展する市場要因、開発段階にある併用療法吸入薬と市場投入スケジュール、吸入薬メーカーとそのアライアンスパートナーに対する経済・技術・規制要因の影響などについて分析しており、コンビネーション吸入薬の市場データと予測、および主要企業のプロファイルなどをまとめ、お届けいたします。
Combination inhalers - oral inhalers containing two drugs that complement the therapeutic actions of one another - have seen a significant increase in development activity and product proliferation in the past five years. Growth is being driven by improved patient experience as derived from ease-of use (fewer devices/medications to administer) and for many patients improved control of symptoms associated with upper airway diseases. Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are realizing significant commercial success in the two markets for which they are indicated - Asthma and COPD - both of which are forecast to grow at impressive rates for the remainder of the decade.
The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
‘The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. The current trend in asthma and COPD inhaler evolution has seen an increase in the incorporation of ergonomic features by device designers aimed at increasing patient receptiveness. Recent inhaler designs have approached the goals of improved usability and patient adherence from a number of distinct directions, including dose preparation technology, dose packaging, novel formulation technology, dosing confirmation, and symptoms monitoring.’
Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.